NasdaqGS:CYTKBiotechs
Is It Too Late To Consider Cytokinetics (CYTK) After Its 45% One-Year Surge?
If you are wondering whether Cytokinetics is still fairly priced after a strong run, or if the recent share price leaves more upside on the table, this article walks through what the current market price might be implying about the business.
Cytokinetics shares recently closed at US$62.34, with returns of 1.0% year to date and 45.8% over the past year, so the stock has already seen meaningful moves that matter for anyone thinking about value today.
Recent attention on Cytokinetics has been...